AstraZeneca 2025 h1: Revenue Hits $28 Billion! Enhertu Surges to $2.289 Billion, TSLP Antibody Up 73%

On July 29, AstraZeneca announced its financial results for the first half of 2025. Total revenue reached $28.045 billion (+11%), with product sales accounting for $27.963 billion (+11%). R&D investment was $6.707 billion, representing a 16% year-on-year increase.

Regional Breakdown: In the first six months of 2025, revenue from the U.S. market totaled $11.97 billion (+12%), while emerging markets contributed $7.697 billion (+12%). Of that, China accounted for $3.515 billion (+5%), making up 13% of AstraZeneca's global revenue.

Business Segments: AstraZeneca operates across five major segments: Oncology, CVRM (Cardiovascular, Renal, and Metabolism), Respiratory & Immunology (R&I), Vaccines & Immune Therapies (V&I), and Rare Diseases. These segments contributed revenues of $11.954 billion (+16%), $6.512 billion (+7%), $4.234 billion (+13%), $411 million (+18%), and $4.336 billion (+3%), respectively. Oncology remained the largest segment, accounting for 43% of total product revenue.

Oncology Highlights

Tagrisso (Osimertinib) continued its steady growth, generating $3.488 billion (+10%) in h2. The drug now covers stage III NSCLC in the U.S., China, EU, and Japan. In June, it was approved in China for second-line treatment of MET-amplified NSCLC in combination with Savolitinib, marking the first fully oral combination therapy for this group.

Other notable oncology drugs include:

• Enhertu (Trastuzumab Deruxtecan): Expanded in January and April in the U.S. and EU to treat HER2-low breast cancer. h2 revenue reached $1.262 billion (+38%). Including Daiichi Sankyo’s reported revenue, sales totaled $2.289 billion (+29%).
• Datroway (Datopotamab Deruxtecan): Approved in the U.S. in January for HR+/HER2- breast cancer and EGFR-mutant NSCLC. Generated $14 million in h2.
• Truqap (Capivasertib): A promising new oncology drug with h2 revenue of $302 million, nearly matching its 2024 full-year sales of $430 million. Expected to become a blockbuster in 2026.

CVRM Segment

While Farxiga (Dapagliflozin) maintained strong growth, newer products like Lokelma (Sodium Zirconium Cyclosilicate) and Wainua (Eplontersen) are gaining market traction. Notably, baxdrostat—a novel antihypertensive agent—completed its Phase III trial this month and may become a major growth driver.

Respiratory & Immunology

Key performers in this area included:

• Breztri Aerosphere (Budesonide/Glycopyrronium/Formoterol): for COPD
• Tezspire (Tezepelumab): for asthma
• Saphnelo (Anifrolumab): for systemic lupus erythematosus

Vaccines & Immune Therapies

Beyfortus (Nirsevimab), an RSV-neutralizing antibody, led the segment with impressive growth—sales more than tripled year-over-year to $238 million. A new competitor, Enflonsia (Clesrovimab) developed by Merck, was approved by the FDA in June.

Rare Diseases

Ultomiris (Ravulizumab), a second-generation C5 monoclonal antibody, delivered excellent results with h2 sales of $2.228 billion (+24%).

AstraZeneca anticipates high single-digit growth for the full year 2025, with multiple regulatory milestones and Phase III readouts expected.